Drug intelligence / Profile preview

EDP011

Development stage: Preclinical
Lead developer: Genor Biopharma
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes

Overview

EDP011 is a recombinant fusion protein currently under development by Genor Biopharma for the treatment of solid tumours. It is part of the company's antibody-based biologics platform. While the specific molecular targets and detailed mechanism of action have not been publicly disclosed, the drug is designed as a fusion protein to address oncological indications. It represents part of Genor Biopharma's expanding pipeline of biologics aimed at treating various cancers and immune-related conditions.

Beyond the preview

Go deeper on EDP011.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EDP011.

Explore the full profile